The robustness of business strategies are reviewed by the management at regular intervals. The business plans are modified and improvements made as an ongoing process.

The medium term strategy of Aanjaneya is to continuously globalize the intellectual property assets and enhance value to customers.

In global markets, the Company shall retain and enhance cost efficient quality leadership in anti malarial drugs. It is the endeavour of the Company to achieve this by resolving complex chemistry challenges, improving process efficiencies, adopting global scale manufacturing and using cost effective market networks throughout South East Asia, Africa and Latin America.

The Company’s competitive advantage is in capturing a large portfolio of approvals, backed up by a global standard R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost efficient manufacturing environment complying to US FDA and EU authorities.

The Company shall forge alliances with original research companies in the area of custom synthesis. The existing relationships and credibility will help Aanjaneya to acquire a significant part of bulk manufacturing of original research companies into its units.

The corporate plans are to ensure growth through organic & inorganic means, and by adopting strategic joint ventures and alliances. The objective is to maximize the revenues and reduce risks.
The long term growth strategies being put in to action include,

Develop a broad portfolio of DMFs through non-infringing processes and intellectual properties and become a significant player in the generics market, especially in the regulated markets.

Manage cost efficiently in a mega-manufacturing environment approved by USFDA/European regulatory authorities; and in the process, enhance our attractiveness to alliance partners.

Emerge as a leading player in global high quality innovative specialty generic formulations and domestic brand segments.